Liver-Targeted Nanostructured PKC Inhibitors for Septic Cholestasis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for septic cholestasis, which is a severe complication of sepsis, are ineffective and risky due to systemic administration of kinase inhibitors that suppress the immune system, leading to life-threatening side effects.

Innovation Solution

A selective nanostructured delivery system targeting PKC inhibitors directly to the liver using carbohydrate moieties, such as ASGPR ligands, to minimize systemic immune suppression and treat septic cholestasis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If kinase inhibitors are administered systemically to treat septic cholestasis, then the treatment effect on cholestasis is improved, but immune system suppression occurs leading to life-threatening side effects

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidimmune system suppression

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent divides the treatment approach into two separate components: (1) a delivery system that segments the therapeutic agent for targeted delivery to the liver, and (2) the kinase inhibitor itself. The delivery system uses size-based filtration in the liver sinusoids to achieve selective delivery, separating the therapeutic effect from systemic exposure and thus resolving the contradiction between treatment effectiveness and immune suppression.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent introduces a delivery system as an intermediary between the kinase inhibitor and the systemic circulation. This intermediary (the delivery system with size-based release mechanism) allows the drug to reach its target in the liver without immediate systemic distribution, thereby maintaining treatment effectiveness while minimizing harmful immune suppression.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If high doses of kinase inhibitors are used to achieve therapeutic effect, then cholestasis treatment is improved, but adverse effects are intensified

Engineering Contradiction:

Improvetreatment efficacyVSAvoidadverse effects

Core Design Contradiction:

ProductivityVSObject-generated harmful factors

Solution Approach 1:

The patent applies local quality by concentrating the therapeutic agent specifically in the liver tissue rather than distributing it uniformly throughout the body. The size-based release mechanism ensures that the high dose required for therapeutic effect is delivered locally to the liver sinusoids and hepatocytes, while minimizing exposure elsewhere, thus achieving treatment efficacy without proportionally intensifying adverse effects.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The delivery system segments the drug release process into two stages: (1) passage through liver sinusoids where size-based filtration occurs, and (2) localized release in the liver tissue. This segmentation allows high local concentration for therapeutic effect while limiting systemic exposure and associated adverse effects.

Inventive Principle:

Principle #1Segmentation

3Productivity

If kinase inhibitors are administered to treat septic cholestasis, then bile flow improvement is achieved, but risk of life-threatening side effects increases

Engineering Contradiction:

Improvebile flow restorationVSAvoidsafety

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The delivery system serves as an intermediary that enables safe administration of kinase inhibitors. It mediates between the need for therapeutic dosing and the risk of life-threatening side effects by providing size-based targeted delivery to the liver, ensuring that the drug reaches its site of action for bile flow restoration while minimizing exposure that would cause harmful side effects.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent segments the pharmacokinetic profile into liver-specific high concentration (for therapeutic effect on bile flow) and systemic low concentration (for safety). The size-based release mechanism in liver sinusoids creates this segmented distribution, restoring bile flow effectively while reducing the risk of life-threatening side effects from systemic exposure.

Inventive Principle:

Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach effectively treats septic cholestasis by reducing PKC activity in the liver while minimizing systemic adverse effects, providing a safer and more targeted therapy.

Implementation Method 1

the selective nanostructured delivery system comprises at least one carbohydrate targeting moiety and at least one polymer and/or at least one lipid and/or at least one virus-like particle

Methodology Applied

Scientific EffectReceptor-ligand binding:

Data Source

PatentUS20250268913A1PKC inhibitors for the treatment of septic cholestasis with CTM targeting

Publication Date: 2025.08.28 SMARTDYELIVERY

AI summary

The invention relates to inhibitors of the PKC signaling pathway for use in the treatment of septic cholestasis, wherein the inhibitors are targeted into the liver by a selective nanostructured delivery system, wherein the selective nanostructured delivery system comprises at least one carbohydrate targeting moiety and at least one polymer and/or at least one lipid and/or at least one virus-like particle.